# Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

> **NCT02911467** · PHASE1 · TERMINATED · sponsor: **Rahul Aggarwal** · enrollment: 8 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Pyruvate (13C)
- **DEVICE:** MRI

## Key facts

- **NCT ID:** NCT02911467
- **Lead sponsor:** Rahul Aggarwal
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-08
- **Primary completion:** 2020-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2020-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02911467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02911467, "Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02911467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*